Zaviralec fosfatidilinozitol 3-kinaze (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zaviralec fosfatidilinozitol 3-kinaze" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

17nih.gov

4^th place

8^th place

13doi.org

2^nd place

5^th place

5fda.gov

447^th place

409^th place

4semanticscholar.org

11^th place

51^st place

4europa.eu

68^th place

28^th place

1archive.today

14^th place

46^th place

1genengnews.com

low place

7,715^th place

1archive-it.org

910^th place

594^th place

1news-medical.net

8,069^th place

2,798^th place

1federalregister.gov

2,474^th place

7,241^st place

archive-it.org

wayback.archive-it.org

»FDA approves Zydelig for three types of blood cancers«. US Food and Drug Administration. 23. julij 2014. Arhivirano iz prvotnega dne 12. januarja 2017. Pridobljeno 16. septembra 2023.{{navedi splet}}: Vzdrževanje CS1: bot: neznano stanje prvotnega URL-ja (povezava)

archive.today

Flanagan (december 2008). »Zeroing in on PI3K Pathway«. Arhivirano iz prvotnega spletišča dne 24. januarja 2013.{{navedi splet}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

doi.org

Hoxhaj G, Manning BD (Februar 2020). »The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism«. Nature Reviews. Cancer. 20 (2): 74–88. doi:10.1038/s41568-019-0216-7. PMC 7314312. PMID 31686003.
Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA (Oktober 2021). »Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)«. Expert Opinion on Therapeutic Patents. 31 (10): 877–892. doi:10.1080/13543776.2021.1924150. PMID 33970742. S2CID 234360275.
Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (2021). »Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives«. Signal Transduction and Targeted Therapy. 6 (1): 201. doi:10.1038/s41392-021-00572-w. PMC 8165101. PMID 34054126.
Curigliano G, Shah RR (Februar 2019). »Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology«. Drug Safety. 42 (2): 247–262. doi:10.1007/s40264-018-0778-4. PMID 30649751. S2CID 58657824.
Hanlon A, Brander DM (december 2020). »Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors«. Hematology. American Society of Hematology. Education Program. 2020 (1): 346–356. doi:10.1182/hematology.2020000119. PMC 7727518. PMID 33275709.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wu P, Liu T, Hu Y (2009). »PI3K inhibitors for cancer therapy: what has been achieved so far?«. Current Medicinal Chemistry. 16 (8): 916–930. doi:10.2174/092986709787581905. PMID 19275602.
Maira SM, Stauffer F, Schnell C, García-Echeverría C (Februar 2009). »PI3K inhibitors for cancer treatment: where do we stand?«. Biochemical Society Transactions. 37 (Pt 1): 265–272. doi:10.1042/BST0370265. PMID 19143644.
Heavey S, O'Byrne KJ, Gately K (april 2014). »Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC«. Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. PMID 24055012.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Vanhaesebroeck B, Perry MW, Brown JR, André F, Okkenhaug K (Oktober 2021). »PI3K inhibitors are finally coming of age«. Nature Reviews. Drug Discovery. 20 (10): 741–769. doi:10.1038/s41573-021-00209-1. PMC 9297732. PMID 34127844. S2CID 235437841.
Ito K, Caramori G, Adcock IM (april 2007). »Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease«. The Journal of Pharmacology and Experimental Therapeutics. 321 (1): 1–8. doi:10.1124/jpet.106.111674. PMID 17021257. S2CID 1906947.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, in sod. (Februar 2010). »Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors«. Cancer Research. 70 (3): 1164–1172. doi:10.1158/0008-5472.CAN-09-2525. PMID 20103642.
Crabbe T (april 2007). »Exploring the potential of PI3K inhibitors for inflammation and cancer«. Biochemical Society Transactions. 35 (Pt 2): 253–256. doi:10.1042/BST0350253. PMID 17371252.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

dx.doi.org

Blagosklonny MV. Anti-aging: senolytics or gerostatics (unconventional view). Oncotarget. 31. 8. 2021; 12(18): 1821-1835. DOI: 10.18632/oncotarget.28049 PubMed

europa.eu

ema.europa.eu

»Zydelig - idelalisib«. Evropska agencija za zdravila. Pridobljeno 23. septembra 2023.
»Umik vloge za pridobitev dovoljenja za promet z zdravilom Aliqopa (kopanlizib)« (PDF). Evropska agencija za zdravila. 22. januar 2022. Pridobljeno 23. septembra 2023.
»Piqray«. Evropska agencija za zdravila. Pridobljeno 23. septembra 2023.
»EMEA-002890-PIP01-20«. Evropska agencija za zdravila. Pridobljeno 23. septembra 2023.

fda.gov

»FDA approves new treatment for adults with relapsed follicular lymphoma«. Ameriški Urad za prehrano in zdravila. 14. september 2017.
»FDA Approval for duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)«. Ameriški Urad za prehrano in zdravila. 24. september 2018.
»FDA approves first PI3K inhibitor for breast cancer«. Urad za prehrano in zdravila. 24. maj 2019.
»FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma«. Ameriški Urad za prehrano in zdravila (FDA). 5. februar 2021. Pridobljeno 5. februarja 2021. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.

accessdata.fda.gov

»Ukoniq (umbralisib) tablets, for oral use« (PDF). TG Therapeutics.

federalregister.gov

unblock.federalregister.gov

»Federal Register :: Request Access«. unblock.federalregister.gov. Pridobljeno 6. oktobra 2022.

genengnews.com

Flanagan (december 2008). »Zeroing in on PI3K Pathway«. Arhivirano iz prvotnega spletišča dne 24. januarja 2013.{{navedi splet}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

news-medical.net

Study results provide rationale for use of PI3K inhibitors in therapeutic settings. News-medical.net. Vpogled: 5. 11. 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hoxhaj G, Manning BD (Februar 2020). »The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism«. Nature Reviews. Cancer. 20 (2): 74–88. doi:10.1038/s41568-019-0216-7. PMC 7314312. PMID 31686003.
Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA (Oktober 2021). »Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)«. Expert Opinion on Therapeutic Patents. 31 (10): 877–892. doi:10.1080/13543776.2021.1924150. PMID 33970742. S2CID 234360275.
Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (2021). »Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives«. Signal Transduction and Targeted Therapy. 6 (1): 201. doi:10.1038/s41392-021-00572-w. PMC 8165101. PMID 34054126.
Curigliano G, Shah RR (Februar 2019). »Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology«. Drug Safety. 42 (2): 247–262. doi:10.1007/s40264-018-0778-4. PMID 30649751. S2CID 58657824.
Hanlon A, Brander DM (december 2020). »Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors«. Hematology. American Society of Hematology. Education Program. 2020 (1): 346–356. doi:10.1182/hematology.2020000119. PMC 7727518. PMID 33275709.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wu P, Liu T, Hu Y (2009). »PI3K inhibitors for cancer therapy: what has been achieved so far?«. Current Medicinal Chemistry. 16 (8): 916–930. doi:10.2174/092986709787581905. PMID 19275602.
Maira SM, Stauffer F, Schnell C, García-Echeverría C (Februar 2009). »PI3K inhibitors for cancer treatment: where do we stand?«. Biochemical Society Transactions. 37 (Pt 1): 265–272. doi:10.1042/BST0370265. PMID 19143644.
Heavey S, O'Byrne KJ, Gately K (april 2014). »Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC«. Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. PMID 24055012.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Vanhaesebroeck B, Perry MW, Brown JR, André F, Okkenhaug K (Oktober 2021). »PI3K inhibitors are finally coming of age«. Nature Reviews. Drug Discovery. 20 (10): 741–769. doi:10.1038/s41573-021-00209-1. PMC 9297732. PMID 34127844. S2CID 235437841.
Ito K, Caramori G, Adcock IM (april 2007). »Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease«. The Journal of Pharmacology and Experimental Therapeutics. 321 (1): 1–8. doi:10.1124/jpet.106.111674. PMID 17021257. S2CID 1906947.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, in sod. (Februar 2010). »Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors«. Cancer Research. 70 (3): 1164–1172. doi:10.1158/0008-5472.CAN-09-2525. PMID 20103642.
Crabbe T (april 2007). »Exploring the potential of PI3K inhibitors for inflammation and cancer«. Biochemical Society Transactions. 35 (Pt 2): 253–256. doi:10.1042/BST0350253. PMID 17371252.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

ncbi.nlm.nih.gov

Hoxhaj G, Manning BD (Februar 2020). »The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism«. Nature Reviews. Cancer. 20 (2): 74–88. doi:10.1038/s41568-019-0216-7. PMC 7314312. PMID 31686003.
Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (2021). »Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives«. Signal Transduction and Targeted Therapy. 6 (1): 201. doi:10.1038/s41392-021-00572-w. PMC 8165101. PMID 34054126.
Hanlon A, Brander DM (december 2020). »Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors«. Hematology. American Society of Hematology. Education Program. 2020 (1): 346–356. doi:10.1182/hematology.2020000119. PMC 7727518. PMID 33275709.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Vanhaesebroeck B, Perry MW, Brown JR, André F, Okkenhaug K (Oktober 2021). »PI3K inhibitors are finally coming of age«. Nature Reviews. Drug Discovery. 20 (10): 741–769. doi:10.1038/s41573-021-00209-1. PMC 9297732. PMID 34127844. S2CID 235437841.
Blagosklonny MV. Anti-aging: senolytics or gerostatics (unconventional view). Oncotarget. 31. 8. 2021; 12(18): 1821-1835. DOI: 10.18632/oncotarget.28049 PubMed

semanticscholar.org

api.semanticscholar.org

Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA (Oktober 2021). »Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)«. Expert Opinion on Therapeutic Patents. 31 (10): 877–892. doi:10.1080/13543776.2021.1924150. PMID 33970742. S2CID 234360275.
Curigliano G, Shah RR (Februar 2019). »Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology«. Drug Safety. 42 (2): 247–262. doi:10.1007/s40264-018-0778-4. PMID 30649751. S2CID 58657824.
Vanhaesebroeck B, Perry MW, Brown JR, André F, Okkenhaug K (Oktober 2021). »PI3K inhibitors are finally coming of age«. Nature Reviews. Drug Discovery. 20 (10): 741–769. doi:10.1038/s41573-021-00209-1. PMC 9297732. PMID 34127844. S2CID 235437841.
Ito K, Caramori G, Adcock IM (april 2007). »Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease«. The Journal of Pharmacology and Experimental Therapeutics. 321 (1): 1–8. doi:10.1124/jpet.106.111674. PMID 17021257. S2CID 1906947.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)